Who
Ferreira Juan Camilo Arjona
Head of R&D & CMO
Company insider
Files Form 4 as: Head of R&D & CMO, Organon & Co; Chief Medical Officer, Myovant Sciences.
In numbers
- Trades disclosed
- 144
- Buys
- 0
- Sells
- 38
- Bought
- $0
- Sold
- $3.9M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 15 Aug 2017
- Last trade
- 11 Aug 2026
- Last filed
- 12 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Aug 2026filed 12 Aug 2026 | OGN Organon & CoPharmaceuticals | SEC FORM 4 Code M | —11,519 at $0.00 | filing |
| 11 Aug 2026filed 12 Aug 2026 | OGN Organon & CoPharmaceuticals | SEC FORM 4 Code F | $56K4,134 at $13.62 | filing |
| 11 Aug 2026filed 12 Aug 2026 | OGN Organon & Cooption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —11,519 at $0.00 | filing |
| 11 Aug 2026filed 12 Aug 2026 | OGN Organon & Cooption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —11,519 at $0.00 | filing |
| 11 Aug 2026filed 12 Aug 2026 | OGN Organon & CoPharmaceuticals | SEC FORM 4 Code M | —11,519 at $0.00 | filing |
| 11 Aug 2026filed 12 Aug 2026 | OGN Organon & CoPharmaceuticals | SEC FORM 4 Code F | $56K4,134 at $13.62 | filing |
| 31 Mar 2026filed 2 Apr 2026 | OGN Organon & CoPharmaceuticals | SEC FORM 4 Code M | —13,431 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | OGN Organon & CoPharmaceuticals | SEC FORM 4 Code F | $27K4,820 at $5.70 | filing |
| 31 Mar 2026filed 2 Apr 2026 | OGN Organon & Cooption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —200,333 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | OGN Organon & Cooption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —200,333 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | OGN Organon & Cooption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —13,431 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | OGN Organon & Cooption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —13,431 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | OGN Organon & CoPharmaceuticals | SEC FORM 4 Code M | —13,431 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | OGN Organon & CoPharmaceuticals | SEC FORM 4 Code F | $27K4,820 at $5.70 | filing |
| 29 Mar 2026filed 31 Mar 2026 | OGN Organon & CoPharmaceuticals | SEC FORM 4 Code M | —8,865 at $0.00 | filing |
| 29 Mar 2026filed 31 Mar 2026 | OGN Organon & CoPharmaceuticals | SEC FORM 4 Code F | $19K3,181 at $5.84 | filing |
| 29 Mar 2026filed 31 Mar 2026 | OGN Organon & Cooption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —8,865 at $0.00 | filing |
| 29 Mar 2026filed 31 Mar 2026 | OGN Organon & Cooption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —8,865 at $0.00 | filing |
| 29 Mar 2026filed 31 Mar 2026 | OGN Organon & CoPharmaceuticals | SEC FORM 4 Code M | —8,865 at $0.00 | filing |
| 29 Mar 2026filed 31 Mar 2026 | OGN Organon & CoPharmaceuticals | SEC FORM 4 Code F | $19K3,181 at $5.84 | filing |
News
No headline names them, or the companies they trade most, lately.